Advanced Search

 

Study ID Status Title Patient Level Data
29060/523 Completed Open prospective study to evaluate the efficacy and safety of paroxetine in the treatment of Panic Disorder and Obsessive-Compulsive Disorder
29060/524 Completed An open multicentre prospective study to compare antidepressive activity of paroxetine in monotherapy and paroxetine combined with pindolol in the treatment of depression
29060/525 Completed A double blind, multicenter randomized drug-controlled study to assess the efficacy and tolerance of paroxetine compared with clomipramine in treatment of panic disorder.
29060/526 Completed A double blind, multicenter, randomized, drug-controlled study to assess the efficacy and tolerance of paroxetine compared with clomipramine in treatment of obsessive compulsive disorder.
29060/533 Completed A study to demonstrate the bioequivalence between the paroxetine capsule and the Paxil tablet formulations at the highest and lowest dosage strengths.
29060/536 Completed A Randomized, Open Trial to Compare Patient Medication Compliance, Efficacy and Quality of Life in Patients Receiving Paroxetine, (20 mg OD) Dispensed in Bottles Compared with Paroxetine, (20 mg OD) Dispensed in Blister Packaging
29060/539 Completed A single dose two-period crossover study to demonstrate bioequivalence between the controlled release paroxetine tablet (25 mg) manufactured at Cidra and Crawley
29060/560 Completed A single dose two-period cross-over study to compare the bioavailability of a paroxetine/pindolol combination tablet (containing 20 mg paroxetine and 7.5 mg controlled release pindolol) when administered in the fed and fasted state
29060/563 Completed A single dose, five-period crossover study to assess the bioavailability of paroxetine from the controlled release paroxetine tablet (50 mg) when administered in four different fed states relative to administration in the fasted state.
29060/564 Completed A steady state study to assess the pharmacokinetic profile of paroxetine after repeated daily dosing of the controlled release paroxetine tablet (25 mg) when given fasted and when given immediately after a standard FDA high-fat breakfast
29060/569 Completed A single dose, four period crossover replicate study to demonstrate bioequivalence between controlled release paroxetine tablets (2 x 12.5mg) manufactured at Cidra and Crawley.
29060/572 Completed A single dose, two-period crossover study to compare the bioavailability of paroxetine from the dispersible tablet (20 mg, final formulation) when administered in the fasted state and after a standard FDA high-fat breakfast
29060/578 Completed A single dose, group sequential, four period crossover study to demonstrate bioequivalence between 37.5 mg and 12.5 mg + 25 mg controlled release paroxetine tablets manufactured at Cidra
29060/579 Completed A single dose, four-period crossover study to demonstrate bioequivalence between 25mg controlled-release paroxetine tablets manufactured at Cidra and Crawley.
29060/595 Completed A Study of the Maintained Efficacy and Safety of Paroxetine versus Placebo in the Long-Term Treatment of Social Phobia
29060/621 Completed A randomized, double-blind, placebo-controlled trial of intermittent treatment with paroxetine 10mg/day and 20mg/day versus placebo in Canadian women with Premenstrual Dysphoric Disorder
29060/622 Completed Open study to evaluate the efficacy and safety of paroxetine in the treatment of minor depression.
29060/625 Completed A double-blind, placebo-controlled multi-centre study to evaluate the efficacy and tolerability of Paroxetine in the treatment of post-stroke depression. Study Listed on ClinicalStudyDataRequest.com
29060/627 Completed A 12-Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering from Post-traumatic Stress Disorder (PTSD) Study Listed on ClinicalStudyDataRequest.com
29060/637 Completed A double-blind, placebo controlled study to evaluate the efficacy and tolerability of paroxetine in patients with Generalised Anxiety Disorder (GAD) Study Listed on ClinicalStudyDataRequest.com
29060/641 Completed A Randomized, Double-Blind, Placebo Controlled, Fixed Dosage Trial to Evaluate the Efficacy and Tolerability of 20 and 40mg/day Paroxetine in Patients with Generalized Anxiety Disorder Study Listed on ClinicalStudyDataRequest.com
29060/642 Completed A Randomized, Double-Blind, Placebo Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine in Patients with Generalized Anxiety Disorder Study Listed on ClinicalStudyDataRequest.com
29060/645 Completed A single-dose, group sequential, four period crossover study to demonstrate bioequivalence between 50 mg and two 25 mg controlled release paroxetine tablets manufactured at Cidra
29060/646 Completed A Study of the Maintained Efficacy and Safety of Paroxetine in Patients with Generalized Anxiety Disorder (GAD)
29060/648 Completed A 12 Week, Double-blind, Placebo-controlled, parallel group study to assess the efficacy and tolerability of Paroxetine in Patients suffering from Post-traumatic Stress Disorder (PTSD) Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.